PMID-25096243 – Melanocortin Receptor Agonists in Sexual Dysfunction
Uckert S, Bannowsky A, Albrecht K, Jünemann KP. "Melanocortin receptor agonists in the treatment of male and female sexual dysfunction: results from basic research and clinical studies," Expert Opin Investig Drugs, 2014;23(11):1477-1483.
Quick Reference
| Property | Value |
|---|---|
| PMID | 25096243 |
| DOI | 10.1517/13543784.2014.934805 |
| Year | 2014 |
| Journal | Expert Opinion on Investigational Drugs |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (class review) |
| Peptide(s) Studied | PT-141, Melanotan II |
Key Findings
- Comprehensive class review of melanocortin receptor (MCR) agonists for sexual dysfunction
- Covers Melanotan I (afamelanotide), Melanotan II, and bremelanotide (PT-141) pharmacology
- MC4R identified as the primary receptor subtype mediating sexual arousal effects
- Melanotan II was the first MCR agonist shown to induce erections in human males (Wessells 1998)
- Bremelanotide (cyclic heptapeptide metabolite of MT-II) was developed as a more targeted agent
- Both peripheral (genital tissue) and central (hypothalamic/limbic) melanocortin pathways contribute to sexual response
- Discusses the shift from intranasal to subcutaneous delivery due to blood pressure concerns with IN route
- Reviews evidence in both male erectile dysfunction and female sexual arousal/desire disorders
Study Design
Narrative review synthesizing preclinical pharmacology, receptor biology, and early-phase clinical trial data for the melanocortin receptor agonist class in the context of male and female sexual dysfunction treatment.
Limitations
- Published before Phase 3 RECONNECT trial results and FDA approval of bremelanotide
- Limited discussion of long-term safety data
- Does not address the safety concerns specific to unregulated Melanotan II use
- Some referenced studies had small sample sizes
Clinical Relevance
This review provides important pharmacological context for understanding the relationship between Melanotan II (the parent compound) and PT-141 (bremelanotide, the clinically developed derivative). For practitioners, it clarifies why MC4R agonism produces sexual effects distinct from PDE5 inhibitors and why both male and female patients may benefit. The dual peripheral-central mechanism explains the broader arousal enhancement (desire + physical response) seen clinically.
Related
#research #narrative-review #evidence-level-V